748046
Last Update Posted: 2014-06-25
Recruiting has ended
Males accepted | 18 Years + |
10 Estimated Participants | No Expanded Access |
Interventional Study | Does not accept healthy volunteers |
Alpharadin™ (Radium-223 Chloride) Safety and Dosimetry With HRPC That Has Metastasized to the Skeleton
The purpose of the study is to investigate the safety, biodistribution, radiation dosimetry and pharmacokinetics of three intravenous escalating dose levels of Xofigo (Alpharadin).
Within the U.S., the trial is conducted under an IND sponsored by Bayer.
Eligibility
Relevant conditions:
Prostate Cancer
Metastases
Pharmacokinetics
If you aren't sure if you meet the criteria above speak to your healthcare professional. Criteria may be updated but not reflected here, do not hesitate to contact the study if you think are close to fitting criteria.
locations
Data sourced from ClinicalTrials.gov